-
September 7, 2011
UK watchdog changes mind to back bone cancer drug
LONDON(Reuters) - Britain's health costs watchdog NICE has decided to back Japanese drugmaker Takeda's bone cancer drug Mepact after re-assessing the impact of a discount on the medicine for patients in the state-funded National Health Service (NHS).
-
June 22, 2009
Whites at greatest risk for rare bone cancer
CHICAGO (Reuters) - Whites in the United States are nine times more likely than blacks to get Ewing's sarcoma, a rare cancer of the bone and soft tissue, U.S. researchers said on Monday.
-
December 3, 2008
Children with bone cancer at risk for second cancer
NEW YORK (Reuters Health) - Children who survive bone cancer have a modest risk of developing a second "solid organ" cancer elsewhere in the body later in life, a long-term follow-up study confirms.